Protective effect of the phosphodiesterase III inhibitor cilostazol on amyloid β-induced cognitive deficits associated with decreased amyloid β accumulation

Biochemical and Biophysical Research Communications

Volumn 408, Issue 4, 2011, Pages 602-608

  Park, Sun Haeng ^a   Kim, Ji Hyun ^a   Bae, Sun Sik ^b   Hong, Ki Whan ^b   Lee, Dong Seok ^c   Leem, Jae Yoon ^d   Choi, Byung Tae ^a   Shin, Hwa Kyoung ^a  

^a Pusan National University   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Kyungpook National University   (South Korea)

^d Woosuk University   (South Korea)

Author keywords

Alzheimer's disease; Amyloid ; ApoE; Microglia; Phosphorylated tau

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; CD11B ANTIGEN; CILOSTAZOL; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; TAU PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LYSATE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG MECHANISM; IMMUNOREACTIVITY; IN VITRO STUDY; LEARNING; MICROGLIA; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; COGNITION DISORDERS; HUMANS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PHOSPHODIESTERASE 3 INHIBITORS; PHOSPHORYLATION; SPATIAL BEHAVIOR; TAU PROTEINS; TETRAZOLES;

MUS;

EID: 79956209877     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.04.068     Document Type: Article

References (26)

1. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
2. Golde T.E. Disease modifying therapy for AD?. J. Neurochem. 2006, 99:689-707.
3. Huang Y., Liu X.Q., Wyss-Coray T., Brecht W.J., Sanan D.A., Mahley R.W. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc. Natl. Acad. Sci. USA 2001, 98:8838-8843.
4. Holtzman D.M., Bales K.R., Tenkova T., Fagan A.M., Parsadanian M., Sartorius L.J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S.M. Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000, 97:2892-2897.
5. Puzzo D., Vitolo O., Trinchese F., Jacob J.P., Palmeri A., Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci. 2005, 25:6887-6897.
6. De Felice F.G., Wasilewska-Sampaio A.P., Barbosa A.C., Gomes F.C., Klein W.L., Ferreira S.T. Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 2007, 4:263-271.
7. Lee J.H., Park S.Y., Shin Y.W., Hong K.W., Kim C.D., Sung S.M., Kim K.Y., Lee W.S. Neuroprotection by cilostazol, a phosphodiesterase type 3 inhibitor, against apoptotic white matter changes in rat after chronic cerebral hypoperfusion. Brain Res. 2006, 1082:182-191.
8. Arai H., Takahashi T. A combination therapy of donepezil and cilostazol for patients with moderate Alzheimer disease: pilot follow-up study. Am. J. Geriatr. Psychiatry 2009, 17:353-354.
9. S.H. Park, J.H. Kim, S.S. Bae, K.W. Hong, B.T. Choi, H.K. Shin, Phosphodiesterase III inhibitor cilostazol protects amyloid β-induced neuronal cell injury via peroxisome proliferator-activated receptor-γ activation, J. Life Sci., in press.
10. Takeda S., Sato N., Niisato K., Takeuchi D., Kurinami H., Shinohara M., Rakugi H., Kano M., Morishita R. Validation of Abeta1-40 administration into mouse cerebroventricles as an animal model for Alzheimer disease. Brain Res. 2009, 1280:137-147.
11. Kim J., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
12. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., Piccardo P., Ghetti B., Paul S.M. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
13. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. ApoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 2008, 118:4002-4013.
14. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
15. Yasojima K., Akiyama H., McGeer E.G., McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 2001, 297:97-100.
16. Qiu W.Q., Walsh D.M., Ye Z., Vekrellis K., Zhang J., Podlisny M.B., Rosner M.R., Safavi A., Hersh L.B., Selkoe D.J. Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J. Biol. Chem. 1998, 273:32730-32738.
17. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response?. Nat. Med. 2006, 12:1005-1015.
18. Wegiel J., Wisniewski H.M. The complex of microglial cells and amyloid star in three-dimensional reconstruction. Acta Neuropathol. 1990, 81:116-124.
19. Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., De Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 2008, 451:720-724.
20. Luber-Narod J., Rogers J. Immune system associated antigens expressed by cells of the human central nervous system. Neurosci. Lett. 1988, 94:17-22.
21. Mackenzie I.R., Munoz D.G. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998, 50:986-990.
22. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K.H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P.A., Waridel C., Calhoun M.E., Jucker M., Probst A., Staufenbiel M., Sommer B. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc. Natl. Acad. Sci. USA 1997, 94:13287-13292.
23. Itagaki S., McGeer P.L., Akiyama H., Zhu S., Selkoe D. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J. Neuroimmunol. 1989, 24:173-182.
24. Yankner B.A., Duffy L.K., Kirschner D.A. Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science 1990, 250:279-282.
25. Yamada K., Nabeshima T. Animal models of Alzheimer's disease and evaluation of anti-dementia drugs. Pharmacol. Ther. 2000, 88:93-113.
26. Kim D.H., Kim S., Jeon S.J., Son K.H., Lee S., Yoon B.H., Cheong J.H., Ko K.H., Ryu J.H. The effects of acute and repeated oroxylin A treatments on Abeta(25-35)-induced memory impairment in mice. Neuropharmacology 2008, 55:639-647.